Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced inducement grants for 10 newly-hired employees. The compensation committee approved stock options to purchase 52,750 shares and restricted stock units (RSUs) covering 36,975 shares of BioCryst common stock, granted on December 31, 2024.
The stock options have an exercise price of $7.52 per share, matching the closing price on the grant date. Both options and RSUs will vest in four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
BioCryst Pharmaceuticals (BCRX) has granted stock-based compensation to five newly-hired employees as employment inducements. The package includes stock options to purchase 17,400 shares and restricted stock units (RSUs) covering 12,150 shares of common stock. The options were granted at an exercise price of $7.50 per share, matching the closing price on November 29, 2024.
Both options and RSUs will vest over four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that Ireland's Health Services Executive (HSE) has recommended ORLADEYO (berotralstat) for routine prevention of hereditary angioedema (HAE) attacks in patients 12 years and older. This marks the introduction of the first oral, once-daily therapy for HAE attack reduction in Ireland. The recommendation follows the European Commission's marketing authorization granted in April 2021. ORLADEYO is currently licensed in 44 countries.
BioCryst Pharmaceuticals (BCRX) has announced its participation in three upcoming investor conferences. The company will present at the 2024 Jefferies London Healthcare Conference on November 20 at 5:00 a.m. ET, the 7th Annual Evercore HealthCONx Conference in Coral Gables on December 4 at 2:35 p.m. ET, and the Piper Sandler 36th Annual Healthcare Conference in New York on December 5 at 8:30 a.m. ET. Live audio webcasts and replays will be available through BioCryst's website investor section.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced inducement grants for five newly-hired employees. The compensation package includes stock options to purchase 18,200 shares at $8.01 per share and restricted stock units (RSUs) covering 12,750 shares. Both options and RSUs will vest over four equal annual installments starting one year from the October 31, 2024 grant date. The stock options have a 10-year term, and all grants were made under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
BioCryst Pharmaceuticals reported strong Q3 2024 financial results, with ORLADEYO net revenue reaching $116.3 million, a 35.7% year-over-year increase. The company achieved a GAAP operating profit of $7.7 million and adjusted its full-year 2024 ORLADEYO revenue guidance to $430-435 million. Total product revenue guidance for 2024 is set at $443-448 million. The company reported progress with BCX17725 for Netherton syndrome entering clinical trials and expects to be approaching quarterly positive EPS by second half of 2025.
BioCryst Pharmaceuticals presented new real-world evidence for ORLADEYO® (berotralstat), showing high adherence and persistence rates comparable to other HAE long-term prophylactic therapies. The study revealed that 86% of ORLADEYO patients filled at least two prescriptions, with 77% adherence and 71% persistence rates at 12 months.
Additional data demonstrated significant HAE attack rate reductions after ORLADEYO initiation, regardless of C1-inhibitor status. Patient survey results indicated a preference for oral therapy, with 54% choosing oral daily treatment over injectable options when efficacy is equal.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024. The company's management team will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial results and provide a corporate update.
Interested parties can access the live call by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. Additionally, a live webcast and replay of the call will be available in the investors section of the company's website at www.biocryst.com.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced new real-world evidence on ORLADEYO® (berotralstat), showing significant reductions in healthcare resource utilization (HRU) for patients with hereditary angioedema (HAE) in the United States. The study, to be presented at the AMCP Nexus 2024 meeting, revealed:
- 34% reduction in all-cause hospitalizations
- 52% reduction in angioedema-related hospitalizations
- 51% reduction in HAE attack-related visits
- 39% reduction in use of on-demand therapies
The retrospective pre-post study analyzed U.S. claims data from 260 patients who initiated ORLADEYO between December 2020 and December 2022. Dr. Sandra Christiansen, from the University of California, San Diego, highlighted the study's importance in demonstrating ORLADEYO's clinical and financial value as a prophylactic therapy for HAE.
BioCryst Pharmaceuticals (Nasdaq: BCRX) will present four abstracts on ORLADEYO® (berotralstat) at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston from October 24-28, 2024. ORLADEYO is an oral, once-daily treatment for hereditary angioedema (HAE) prophylaxis in patients 12 years and older.
The presentations will focus on:
- Adherence and persistence among HAE patients treated with berotralstat and other therapies
- Sustained real-world attack reductions in HAE patients with and without C1-inhibitor deficiency
- Long-term prophylactic treatment preferences of HAE patients
The posters will be displayed in the exhibit hall at specific times and will also be accessible online to registered attendees starting October 24 at 8:00 a.m. ET on ACAAI's website.